CXCL9 and metabolic dysfunction-associated steatohepatitis: Recent studies suggest that CXCL9 promotes NASH development and progression by activating the p-JNK pathway, promoting Th17 cell proliferation, and disrupting Treg/Th17 cell homeostasis in a mouse model of NASH68.